Menu Close
scroll
Urology

COMBAT BRS

COMBined Antineoplastic Thermotherapy Bladder Recirculation System

Overview

The Combat BRS System is an innovative bladder recirculation system designed to deliver.

Several ongoing clinical studies are aimed at demonstrating the clinical evidence of Hyperthermic Intra-VEsical Chemotherapy (HIVEC™):

HIVEC-I      HIVEC-II
Prospective, Randomised International Multicentre Clinical Trials in 598 Intermediate Risk NMIBC Patients. HIVEC-I and II have successfully completed recruitment with data release expected in early 2020.

HIVEC-HR      HIVEC-R      HIVEC-Premito
Further trials encompassing 269 patients are currently evaluating the efficacy of HIVEC at various stages of the NMIBC treatment pathway.



Learn more on:
combatcancer.com
SELECTED PUBLICATIONS
February 2020
Results after two years of follow up after intravesical thermochemotherapy with heated mitomycin 40 in patients with high-risk superficial bladder cancer
Thomas Alexander Voegeli, Eric Frank, Christian Bach, Catejan Nzeh: Results after two years of follow up after intravesical thermochemotherapy with heated mitomycin 40 in patients with high-risk superficial bladder cancer. Journal of Clinical Oncology 38(6_suppl):512-512, February 2020.
May 2018
Hyperthermic Intravesical Chemotherapy for BCG-unresponsive Non-Muscle Invasive Bladder Cancer patients
Joep de Jong, Kees Hendricksen, Marloes Rosier, Joost Boormans, Hugh Mostafid: Hyperthermic Intravesical Chemotherapy for BCG-unresponsive Non-Muscle Invasive Bladder Cancer patients. Journal of Urology, April 2018, Volume 199, Issue 4, Supplement, Pages e1234–e1235.
May 2018
Chemohypertermia with Mitomycin C and COMBAT system in High Risk Non Muscle Invasive Bladder Cancer - a new alternative
Plata Bello A, Garcia Alvarez C, Villacampa F, Gonzalez D, Llanes L, Diaz Goizueta J, Rios E, Rimington P, Castillo JM, Castillo DJ, Pontones JL, Nzeh C, Brisuda A, León J, Sousa A, Chiancone F, Fedelini P, Hendricksen K, Vögeli TA, Frank E, Wilby D: Chemohypertermia with Mitomycin C and COMBAT system in High Risk Non Muscle Invasive Bladder Cancer - a new alternative. Journal of Urology, April 2018, Volume 199, Issue 4, Supplement, Pages e1119, MP83-09.
February 2018
Heat targeted drug delivery - COMBAT - in superficial TCC - First midterm results in a cohort of high-risk patients scheduled for cystectomy
Thomas Alexander Voegeli, Eric Frank, Christian Bach, Catejan Nzeh: Heat targeted drug delivery - COMBAT - in superficial TCC - First midterm results in a cohort of high-risk patients scheduled for cystectomy. Journal of Clinical Oncology 36(6_suppl):442-442 · February 2018.
October 2017
Chemohyperthermia with Mitomycin C and COMBAT System in High Risk Non-Muscle Invasive Bladder Cancer Patients: Initial experience in a single centre
González-Padilla, Daniel A; Guerrero, Felix; González-Díaz, Alejandro; Castellano, Daniel; Duarte, Jose Manuel; De la Rosa, Federico; Villacampa, Felipe: Chemohyperthermia with Mitomycin C and COMBAT System in High Risk Non-Muscle Invasive Bladder Cancer Patients: Initial experience in a single centre. Global Congress on Bladder Cancer 2nd Edition, Poster Presentation 5-6 October 2017, Edinburgh, UK.
October 2017
Hyperthermic Intravesical Chemotherapy for BCG-unresponsive Non-Muscle Invasive Bladder Cancer patients
Joost Boormans, Joep de Jong, Marloes Rosier: Hyperthermic Intravesical Chemotherapy for BCG-unresponsive Non-Muscle Invasive Bladder Cancer patients. Global Congress on Bladder Cancer 2nd Edition, Poster Presentation 5-6 October 2017, Edinburgh, UK.
innoMedicus